Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Rhea-AI Summary

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, NY. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will take part in a panel discussion titled 'Opportunities and Challenges When Small Names Go After Blockbuster Indications'.

Reviva focuses on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases. The conference will provide an opportunity for one-on-one investor meetings with Reviva's management team. Interested parties are advised to contact their ROTH representative for registration and meeting scheduling.

CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 3^rd Annual ROTH Healthcare Opportunities Conference, taking place October 9, 2024, in New York, NY.

3^rd Annual ROTH Healthcare Opportunities Conference
Format: Panel discussion (Opportunities and Challenges When Small Names Go After Blockbuster Indications) and one-on-one investor meetings
Date: Wednesday, October 9, 2024
Time: 8:00 a.m. ET
Location: New York, NY

Please contact your ROTH representative to register for the conference and schedule a one-on-one meeting with Reviva management.

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

When and where is Reviva Pharmaceuticals (RVPH) participating in the ROTH Healthcare Opportunities Conference?

Reviva Pharmaceuticals (RVPH) is participating in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, NY.

What type of discussion will Reviva's CEO participate in at the ROTH conference?

Reviva's CEO, Laxminarayan Bhat, Ph.D., will participate in a panel discussion titled 'Opportunities and Challenges When Small Names Go After Blockbuster Indications' at the ROTH conference.

What therapeutic areas does Reviva Pharmaceuticals (RVPH) focus on?

Reviva Pharmaceuticals (RVPH) focuses on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases.

How can investors schedule meetings with Reviva's management at the ROTH conference?

Investors can contact their ROTH representative to register for the conference and schedule one-on-one meetings with Reviva's management team.